<DOC>
	<DOCNO>NCT01696383</DOCNO>
	<brief_summary>The purpose study evaluate efficacy change DuoTrav® ( Travoprost 0.004 % /Timolol 0.5 % ) prior prostaglandin analogue beta-blocker monotherapy Russian glaucoma patient open-angle glaucoma ocular hypertension whose intraocular pressure ( IOP ) uncontrolled current treatment .</brief_summary>
	<brief_title>Assessing Efficacy DuoTrav Replacement Therapy Glaucoma Patients Russia</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Cloprostenol</mesh_term>
	<criteria>Clinical diagnosis ocular hypertension , primary openangle glaucoma pseudoexfoliative pigment dispersion glaucoma . Be stable IOPlowering regimen prostaglandin analogue betablocker ( monotherapy ) within 4 week prior Screening Visit . Have IOP consider safe ( opinion investigator ) , eye , way assure clinical stability vision optic nerve throughout study period . Have IOP 19 35 mmHg ( time day ) least one eye ( would designate study eye ) . In eye designate study eye , IOP able control pharmacologic therapy study medicine alone . Willing discontinue use ocular hypotensive medication ( ) prior receive study medication entire course study . Able follow instruction willing able attend study visit . Have best correct visual acuity 6/60 ( 20/200 Snellen , 1.0 LogMAR ) good eye . Read , sign , date Ethics Committee review approve informed consent form . Other protocoldefined inclusion criterion may apply . Known medical history allergy , hypersensitivity poor tolerance component DuoTrav® deem clinically significant opinion Principal Investigator . Any abnormality prevent reliable applanation tonometry either eye . Corneal dystrophies either eye . Any opacity subject uncooperativeness restricts adequate examination anterior chamber either eye . Concurrent infectious/noninfectious conjunctivitis , keratitis uveitis either eye . Blepharitis nonclinically significant conjunctival injection allow . History ocular herpes simplex infection . Intraocular conventional surgery laser surgery either eye less three month prior Screening Visit . Risk visual field visual acuity worsen consequence participation study , investigator 's best judgment . Progressive retinal optic nerve disease cause apart glaucoma . Use systemic medication know affect IOP ( e.g. , oral betaadrenergic blocker , alphaagonists blocker , angiotensin convert enzyme inhibitor calcium channel blocker ) , stable course 7 day prior Screening Visit anticipated change dosage course study . Bronchial asthma , history bronchial asthma , severe chronic obstructive pulmonary disease would preclude safe administration topical betablocker . History severe allergic rhinitis . Unwillingness risk possibility darken iris eyelash change . Women childbearing potential use reliable mean birth control least one month prior Screening/Baseline Visit . Women pregnant lactating . Participation investigational study within 30 day prior Screening Visit . Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Intraocular Pressure ( IOP )</keyword>
	<keyword>Glaucoma</keyword>
	<keyword>Ocular hypertension</keyword>
	<keyword>DuoTrav</keyword>
	<keyword>Prostaglandin analogue</keyword>
	<keyword>Beta-blocker</keyword>
</DOC>